Yoshinobu Namba

Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study

Makoto Ueno, Masafumi Ikeda, Chigusa Morizane et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 332 citations

Medicine, Oncology, Chemotherapy +5

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang et al. · Annals of Oncology · 2021 · 199 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141

Naomi Kiyota, Yasuhisa Hasegawa, Shunji Takahashi et al. · Oral Oncology · 2017 · 141 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer

Terufumi Kato, Noriyuki Masuda, Yoichi Nakanishi et al. · Lung Cancer · 2016 · 106 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata et al. · Institutional Repositories DataBase (IRDB) · 2021 · 82 citations · Full text

Medicine, Oncology, Pharmacology +16